{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-26-000083","form_type":"8-K","ticker":"CMPX","cik":"0001738021","company_name":"Compass Therapeutics, Inc.","filed_at":"2026-01-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.038644+00:00","generated_at":"2026-05-16T11:32:49.909063+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Compass Therapeutics reports $209M cash, tovecimig PFS/OS data on track Q1 2026; appoints CCO and CMO","bullets":["Cash and marketable securities estimated at $209M as of Dec 31, 2025; cash runway into 2028.","Analyses of PFS and OS in tovecimig Phase 2/3 BTC trial expected late Q1 2026; BLA preparation underway.","CTX-8371: third confirmed response in Hodgkin Lymphoma; expansions open in TNBC and NSCLC.","Appointed Arjun Prasad as CCO and Cynthia Sirard as CMO effective January 2026.","CTX-10726 Phase 1 initiation expected Q1 2026 with initial data in H2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-000083","json":"https://secwatch.observer/filing/0001171843-26-000083.json","markdown":"https://secwatch.observer/filing/0001171843-26-000083.md","text":"https://secwatch.observer/filing/0001171843-26-000083.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1738021/000117184326000083/0001171843-26-000083-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1738021/000117184326000083/f8k_010626.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:32:49.909063+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}